Celgene fails to win NICE endorsement for Revlimid

The U.K.'s National Institute for Health and Clinical Excellence ruled that Revlimid, a myeloma drug from Celgene, is not cost effective enough to be covered by the National Health Service. Charitable groups are urging the Department of Health to work with Celgene so that NHS patients can have access to the medicine, which has been shown to prolong the lives of people with the bone marrow cancer by as long as three years.

View Full Article in:

Telegraph (London) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations